Alexion Pharmaceuticals Inc. (ALXN) Release: Researchers to Present New Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at American Society of Nephrology Annual Meeting
10/16/2013 10:06:16 AM
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present data from clinical studies of Soliris® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS), a genetic, life-long, ultra-rare disease associated with vital organ failure and premature death.
Help employers find you! Check out all the jobs and post your resume.
comments powered by